

DURECT CORP
Form 8-K
February 17, 2006

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 17, 2006

Date of Report

(Date of earliest event reported)

DURECT CORPORATION

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

000-31615
(Commission File Number)

94-3297098
(I.R.S. Employer
Identification No.)

10240 Bubb Road
Cupertino, CA 95014

Edgar Filing: DURECT CORP - Form 8-K

(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

On February 17, 2006, DURECT Corporation, a Delaware corporation (DURECT), issued a press release announcing that Remoxy, an abuse-resistant pain medicine under development based on DURECT's patented ORADUR technology incorporating the opioid oxycodone has successfully completed a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA) and that a pivotal Phase III trial is being commenced on Remoxy in 400 patients with severe chronic pain.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release of DURECT Corporation dated February 17, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DURECT Corporation

Date: February 17, 2006

By: /s/ James E. Brown

James E. Brown
President and Chief Executive Officer

DURECT CORPORATION

INDEX TO EXHIBITS

| Exhibit Number | Description |
|---------------------------|---|
| 99.1 | Press Release of DURECT Corporation dated February 17, 2006 |